Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is associated with superior weight loss outcomes, according to a study presented at ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.